Solubilized benzoyl peroxide versus benzoyl peroxide/clindamycin in the treatment of moderate acne.

Author(s): Tanghetti E, Kircik L, Wilson D, Dhawan S

Affiliation(s): Center for Dermatology and Laser Surgery, Sacramento, CA 95819, USA. et@mgci.com

Publication date & source: 2008-06, J Drugs Dermatol., 7(6):534-8.

Publication type: Research Support, Non-U.S. Gov't

BACKGROUND: Benzoyl peroxide (BPO) is poorly soluble. A solubilized formulation of BPO has been developed to maximize its bioavailability and enhance follicular penetration. METHODS: Patients with acne vulgaris were randomly assigned to receive solubilized BPO 5% gel on one side of the face and a BPO 5%/clindamycin 1% combination product on the contralateral side, twice daily for 4 weeks. RESULTS: Of 23 patients enrolled, 100% completed the study. Reductions in lesion count with the solubilized BPO gel were at least as great as with BPO/clindamycin--and significantly greater (P< or =.05) for noninflammatory lesions at week 1 and inflammatory lesions at week 4. Both regimens were generally well tolerated and patient satisfaction was comparable. CONCLUSIONS: Solubilized BPO 5% gel monotherapy offers significantly greater efficacy, and comparable patient satisfaction, compared with BPO/clindamycin. The early reduction in lesion counts observed with the solubilized BPO gel in the absence of an antibiotic is clinically relevant.